Vanquish Bio
Vanquish Bio is focused on developing novel cancer therapies using natural killer cell-derived extracellular vesicle technology. The company's mission is to transform cancer from a life-threatening disease into a manageable condition through innovative, safe, and accessible immunotherapies. Their platform leverages NKEVs to target difficult, resistant cancer types, improving therapeutic outcomes with scalable, biocompatible solutions.
Industries
N/A
Products
A cell-free immunotherapeutic platform utilizing vesicles derived from human natural killer cells to target and induce apoptosis in cancer cells, including treatment-resistant and metastatic tumors.
Partnership-driven platform fusing AI-powered imaging for early detection of aggressive cancers and for targeted delivery of extracellular vesicle therapy.
A cell-free immunotherapeutic platform utilizing vesicles derived from human natural killer cells to target and induce apoptosis in cancer cells, including treatment-resistant and metastatic tumors.
Partnership-driven platform fusing AI-powered imaging for early detection of aggressive cancers and for targeted delivery of extracellular vesicle therapy.
Expertise Areas
- Extracellular vesicle-based immunotherapy
- Natural killer cell biology and translational research
- Oncology (refractory, metastatic, and chemotherapy-resistant cancers)
- Artificial intelligence in clinical diagnostics
Key Technologies
- Extracellular vesicle isolation and production
- Natural killer cell-based therapeutic platforms
- Intravenous biologic drug delivery
- AI-driven diagnostic imaging
Key People
Co-Founder and Chief Executive Officer
Vice President, Operations
Co-Founder and Chair, Scientific Advisory Board
Co-Founder and Chief Executive Officer
Vice President, Operations
Co-Founder and Chair, Scientific Advisory Board
News & Updates
Received early-stage capital from the National Cancer Institute to support NK cell-derived extracellular vesicle research.
A foundational article on the phenotype of NK cells.
Article examining antigen involvement in NK cell cytolytic activity.
Study on how CD9 expression affects cytotoxicity in myeloma cell lines.
Research identifying an E3 ligase’s role in NK cell cytolytic ability.
Article describing NKLAM’s impact on NK cell function and tumor growth.
Received early-stage capital from the National Cancer Institute to support NK cell-derived extracellular vesicle research.
A foundational article on the phenotype of NK cells.
Article examining antigen involvement in NK cell cytolytic activity.
Study on how CD9 expression affects cytotoxicity in myeloma cell lines.
Research identifying an E3 ligase’s role in NK cell cytolytic ability.
Article describing NKLAM’s impact on NK cell function and tumor growth.